{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:25:28Z","timestamp":1794565528164,"version":"4.9.1"},"reference-count":94,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011747","name":"Novo Nordisk Foundation Center for Basic Metabolic Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001734","name":"K\u00f8benhavns Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biopsych.2026.04.010","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:10:29Z","timestamp":1777011029000},"page":"805-813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["From the Discovery of GLP-1 to Today\u2019s Diabetes\/Obesity Therapy and Beyond"],"prefix":"10.1016","volume":"100","author":[{"given":"Jens Juul","family":"Holst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2026.04.010_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1042\/bj0010028","article-title":"On the treatment of diabetes melllitus by acid extract of duodenal mucous membrane","volume":"1","author":"Moore","year":"1906","journal-title":"Biochem J"},{"key":"10.1016\/j.biopsych.2026.04.010_bib2","first-page":"20","article-title":"Contributions a l\u2019etude des variation physiologiques de la secretion interne de pancreas: Relations entre les secretions externe et interne du pancreas","volume":"31","author":"Zunz","year":"1929","journal-title":"Archs Int Physiol Biochim"},{"key":"10.1016\/j.biopsych.2026.04.010_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0140-6736(64)90011-X","article-title":"New interpretation of oral glucose tolerance","volume":"2","author":"McIntyre","year":"1964","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.04.010_bib4","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/jcem-37-5-826","article-title":"Stimulation of insulin secretion by gastric inhibitory polypeptide in man","volume":"37","author":"Dupre","year":"1973","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.biopsych.2026.04.010_bib5","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1210\/jcem-69-3-654","article-title":"Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: Interactions with glucose, phenylalanine, and cholecystokinin-8","volume":"69","author":"Nauck","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.biopsych.2026.04.010_bib6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopsych.2026.04.010_bib7","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0026-0495(87)90153-3","article-title":"Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus","volume":"36","author":"Krarup","year":"1987","journal-title":"Metabolism"},{"key":"10.1016\/j.biopsych.2026.04.010_bib8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF00257346","article-title":"Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption","volume":"24","author":"Ebert","year":"1983","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopsych.2026.04.010_bib9","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3109\/00365528009181538","article-title":"Gastric inhibitory polypeptide (GIP) and insulin release after small- bowel resection in man","volume":"15","author":"Lauritsen","year":"1980","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.biopsych.2026.04.010_bib10","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/0016-5085(83)90388-8","article-title":"Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin\u2014current status","volume":"84","author":"Holst","year":"1983","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopsych.2026.04.010_bib11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/BF02346248","article-title":"Radioimmunological determination of pancreatic and gut glucagon in plasma","volume":"7","author":"Heding","year":"1971","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopsych.2026.04.010_bib12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1042\/bj1870337","article-title":"Evidence that glicentin contains the entire sequence of glucagon","volume":"187","author":"Holst","year":"1980","journal-title":"Biochem J"},{"issue":"suppl 2","key":"10.1016\/j.biopsych.2026.04.010_bib13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0196-9781(81)90007-3","article-title":"The amino acid sequence of porcine glicentin","volume":"2","author":"Thim","year":"1981","journal-title":"Peptides"},{"key":"10.1016\/j.biopsych.2026.04.010_bib14","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/289514a0","article-title":"Relationship of glicentin to proglucagon and glucagon in the porcine pancreas","volume":"289","author":"Moody","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2026.04.010_bib15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1073\/pnas.79.2.345","article-title":"Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem","volume":"79","author":"Lund","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2026.04.010_bib16","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/302716a0","article-title":"Hamster preproglucagon contains the sequence of glucagon and two related peptides","volume":"302","author":"Bell","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2026.04.010_bib17","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1210\/endo-119-4-1467","article-title":"Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas","volume":"119","author":"Orskov","year":"1986","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopsych.2026.04.010_bib18","doi-asserted-by":"crossref","first-page":"11880","DOI":"10.1016\/S0021-9258(18)67324-7","article-title":"Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing","volume":"261","author":"Mojsov","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biopsych.2026.04.010_bib19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0014-5793(87)81430-8","article-title":"Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut","volume":"211","author":"Holst","year":"1987","journal-title":"FEBS Lett"},{"key":"10.1016\/j.biopsych.2026.04.010_bib20","doi-asserted-by":"crossref","first-page":"12826","DOI":"10.1016\/S0021-9258(18)51561-1","article-title":"Complete sequences of glucagon-like peptide-1 from human and pig small intestine","volume":"264","author":"Orskov","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biopsych.2026.04.010_bib21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI112855","article-title":"Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas","volume":"79","author":"Mojsov","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1016\/j.biopsych.2026.04.010_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3109\/00365518709168885","article-title":"Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2)","volume":"47","author":"Orskov","year":"1987","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.biopsych.2026.04.010_bib23","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7-36: A physiological incretin in man","volume":"2","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.04.010_bib24","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2337\/db18-1123","article-title":"Separate and combined gluco-metabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in healthy individuals","volume":"68","author":"Gasbjerg","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.biopsych.2026.04.010_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170183","article-title":"Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists","volume":"125","author":"Gasbjerg","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.biopsych.2026.04.010_bib26","doi-asserted-by":"crossref","first-page":"9637","DOI":"10.1016\/S0021-9258(18)67561-1","article-title":"Cell-specific post-translational processing of preproglucagon expressed from a metallothionein-glucagon fusion gene","volume":"261","author":"Drucker","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biopsych.2026.04.010_bib27","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1053\/gast.2001.22555","article-title":"Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon","volume":"120","author":"Jeppesen","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopsych.2026.04.010_bib28","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3109\/00365529709025098","article-title":"Glucagon-like peptide-1 7-36 amide and peptide YY have additive inhibitory effect on gastric acid secretion in man","volume":"32","author":"Wettergren","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.biopsych.2026.04.010_bib29","first-page":"G984","article-title":"Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow","volume":"275","author":"Wettergren","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.biopsych.2026.04.010_bib30","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/00365529409092462","article-title":"Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man","volume":"29","author":"Wettergren","year":"1994","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.biopsych.2026.04.010_bib31","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/gut.40.5.597","article-title":"The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation","volume":"40","author":"Wettergren","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.biopsych.2026.04.010_bib32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bph.15638","article-title":"Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment","volume":"179","author":"Trapp","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2026.04.010_bib33","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s42255-021-00363-1","article-title":"A genetic map of the mouse dorsal vagal complex and its role in obesity","volume":"3","author":"Ludwig","year":"2021","journal-title":"Nat Metab"},{"key":"10.1016\/j.biopsych.2026.04.010_bib34","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/BF01316798","article-title":"Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man","volume":"38","author":"Wettergren","year":"1993","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.biopsych.2026.04.010_bib35","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/00365520410004424","article-title":"Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1","volume":"39","author":"Nagell","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.biopsych.2026.04.010_bib36","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1023\/A:1026678925120","article-title":"Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms","volume":"43","author":"Tolessa","year":"1998","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.biopsych.2026.04.010_bib37","doi-asserted-by":"crossref","first-page":"884","DOI":"10.2337\/dc16-0351","article-title":"Roles of the gut in glucose homeostasis","volume":"39","author":"Holst","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopsych.2026.04.010_bib38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","article-title":"Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus","volume":"62","author":"Kolterman","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.biopsych.2026.04.010_bib39","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1037\/h0034870","article-title":"Cholecystokinin decreases food intake in rats","volume":"84","author":"Gibbs","year":"1973","journal-title":"J Comp Physiol Psychol"},{"key":"10.1016\/j.biopsych.2026.04.010_bib40","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0031-9384(82)90081-6","article-title":"Pancreatic glucagon and postprandial satiety in the rat","volume":"28","author":"Geary","year":"1982","journal-title":"Physiol Behav"},{"key":"10.1016\/j.biopsych.2026.04.010_bib41","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/379069a0","article-title":"A role for glucagon-like peptide-1 in the central regulation of feeding","volume":"379","author":"Turton","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2026.04.010_bib42","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI990","article-title":"Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans","volume":"101","author":"Flint","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.biopsych.2026.04.010_bib43","first-page":"4382","article-title":"A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans","volume":"86","author":"Verdich","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.biopsych.2026.04.010_bib44","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0014-5793(88)80821-4","article-title":"Truncated glucagon-like peptide-1 (proglucagon 78-107 amide), an intestinal insulin-releasing peptide, has specific receptors on rat insulinoma cells (RIN 5AH)","volume":"229","author":"Orskov","year":"1988","journal-title":"FEBS Lett"},{"key":"10.1016\/j.biopsych.2026.04.010_bib45","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0026-0495(94)90164-3","article-title":"Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man","volume":"43","author":"Hvidberg","year":"1994","journal-title":"Metabolism"},{"key":"10.1016\/j.biopsych.2026.04.010_bib46","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2337\/dc15-1643","article-title":"Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12- and 24-week phase 2 studies","volume":"39","author":"Kazda","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopsych.2026.04.010_bib93","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2337\/diacare.15.2.270","article-title":"Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects","volume":"15","author":"Nathan","year":"1992","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopsych.2026.04.010_bib47","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","article-title":"Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients","volume":"36","author":"Nauck","year":"1993","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopsych.2026.04.010_bib48","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.04.010_bib49","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1007\/s001250050613","article-title":"Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM","volume":"39","author":"Nauck","year":"1996","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopsych.2026.04.010_bib50","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/BF00401846","article-title":"Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships","volume":"38","author":"Ritzel","year":"1995","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopsych.2026.04.010_bib51","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects","volume":"44","author":"Deacon","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.biopsych.2026.04.010_bib52","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/jc.2002-021053","article-title":"Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects","volume":"88","author":"Vilsboll","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.biopsych.2026.04.010_bib53","first-page":"952","article-title":"Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo","volume":"80","author":"Deacon","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.biopsych.2026.04.010_bib54","doi-asserted-by":"crossref","first-page":"764","DOI":"10.2337\/diabetes.47.5.764","article-title":"Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig","volume":"47","author":"Deacon","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.biopsych.2026.04.010_bib55","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/diabetes.47.11.1663","article-title":"Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes","volume":"47","author":"Holst","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.biopsych.2026.04.010_bib56","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.2337\/diacare.27.12.2874","article-title":"Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes","volume":"27","author":"Ahren","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopsych.2026.04.010_bib57","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/13543784.16.4.533","article-title":"Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes","volume":"16","author":"Deacon","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.biopsych.2026.04.010_bib58","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s001250050903","article-title":"Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity","volume":"41","author":"Deacon","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopsych.2026.04.010_bib59","first-page":"E458","article-title":"Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig","volume":"271","author":"Deacon","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.biopsych.2026.04.010_bib60","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00125-005-0128-9","article-title":"Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs","volume":"49","author":"Simonsen","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopsych.2026.04.010_bib61","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.biopsych.2026.04.010_bib62","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2337\/diacare.24.8.1416","article-title":"Glucagon-like peptide-1 infusion must be maintained for 24 h\/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment","volume":"24","author":"Larsen","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopsych.2026.04.010_bib63","doi-asserted-by":"crossref","first-page":"21432","DOI":"10.1016\/S0021-9258(19)36628-1","article-title":"Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4","volume":"267","author":"Raufman","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biopsych.2026.04.010_bib64","doi-asserted-by":"crossref","first-page":"8641","DOI":"10.1073\/pnas.89.18.8641","article-title":"Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1","volume":"89","author":"Thorens","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2026.04.010_bib65","doi-asserted-by":"crossref","first-page":"9778","DOI":"10.1074\/jbc.273.16.9778","volume":"273","author":"Pohl","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biopsych.2026.04.010_bib66","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.04.010_bib67","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/17446651.4.2.119","article-title":"Liraglutide Effect and Action in Diabetes (LEAD) trial","volume":"4","author":"Madsbad","year":"2009","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.biopsych.2026.04.010_bib68","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/dmrr.499","article-title":"Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes","volume":"20","author":"Fineman","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.biopsych.2026.04.010_bib69","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.04.010_bib70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2026.04.010_bib71","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1060028014564180","article-title":"Dulaglutide: The newest GLP-1 receptor agonist for the management of type 2 diabetes","volume":"49","author":"Thompson","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.biopsych.2026.04.010_bib72","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.biopsych.2026.04.010_bib73","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.04.010_bib74","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2026.04.010_bib75","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopsych.2026.04.010_bib76","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2026.04.010_bib77","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopsych.2026.04.010_bib78","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","article-title":"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: A multicentre, randomised, dose-response, phase 2 study","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.04.010_bib79","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.cct.2010.06.001","article-title":"Academic perspectives on the United States Food and Drug Administration\u2019s guidance for industry on diabetes mellitus","volume":"31","author":"Hennekens","year":"2010","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.biopsych.2026.04.010_bib80","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/cvr\/cvac112","article-title":"Cardiovascular effects of incretins\u2014focus on GLP-1 receptor agonists","volume":"119","author":"Madsbad","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.biopsych.2026.04.010_bib81","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2026.04.010_bib82","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2337\/dc24-1533","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: A systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopsych.2026.04.010_bib83","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.04.010_bib84","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1111\/dom.70143","article-title":"Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial","volume":"27","author":"Hankosky","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.biopsych.2026.04.010_bib85","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers","volume":"8","author":"Norgaard","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.biopsych.2026.04.010_bib86","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jamaneurol.2025.0360","article-title":"Cardioprotective glucose-lowering agents and dementia risk: A systematic review and meta-analysis","volume":"82","author":"Seminer","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.biopsych.2026.04.010_bib87","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2026.04.010_bib88","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: A Presidential Advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.biopsych.2026.04.010_bib89","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","article-title":"The expanding incretin universe: From basic biology to clinical translation","volume":"66","author":"Drucker","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopsych.2026.04.010_bib90","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1177\/13872877251351329","article-title":"Associations of semaglutide with Alzheimer\u2019s disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study","volume":"106","author":"Wang","year":"2025","journal-title":"J Alzheimers Dis"},{"issue":"10544","key":"10.1016\/j.biopsych.2026.04.010_bib94","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0140-6736(26)00459-9","article-title":"Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): Two phase 3, randomised, placebo-controlled trials","volume":"407","author":"Cummings","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.04.010_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2023.114236","article-title":"Metabolic hormone action in the VTA: Reward-directed behavior and mechanistic insights","volume":"268","author":"Geisler","year":"2023","journal-title":"Physiol Behav"},{"key":"10.1016\/j.biopsych.2026.04.010_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1063033","article-title":"The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies","volume":"14","author":"Jerlhag","year":"2023","journal-title":"Front Pharmacol"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322326011959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322326011959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:49:48Z","timestamp":1794563388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322326011959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":94,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0006322326011959"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2026.04.010","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From the Discovery of GLP-1 to Today\u2019s Diabetes\/Obesity Therapy and Beyond","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2026.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}